Decreased plasma half-life of cyclophosphamide during repeated high-dose administration

Cancer Chemother Pharmacol. 1983;10(3):192-3. doi: 10.1007/BF00255760.


Cyclophosphamide was given as IV doses of 50 mg/kg/day on each of four successive days as treatment for ovarian and lung cancer. Blood samples were taken at regular intervals and analysed for cyclophosphamide by gas liquid chromatography. The plasma half-lives (t 1/2) and volumes of distribution (V D) were calculated for each of the treatment days; t 1/2 was found to decrease with subsequent doses whereas V D was not significantly changed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / blood*
  • Dose-Response Relationship, Drug
  • Female
  • Half-Life
  • Humans
  • Kinetics
  • Lung Neoplasms / blood*
  • Lung Neoplasms / drug therapy
  • Male
  • Ovarian Neoplasms / blood*
  • Ovarian Neoplasms / drug therapy


  • Cyclophosphamide